<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02350205</url>
  </required_header>
  <id_info>
    <org_study_id>LOEX 014</org_study_id>
    <nct_id>NCT02350205</nct_id>
  </id_info>
  <brief_title>SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma</brief_title>
  <official_title>SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to assess the safety, effectiveness and benefits of Self&#xD;
      Assembled Skin Substitute SASS grafts as a permanent skin replacement for the treatment of&#xD;
      full-thickness burn wounds that require permanent coverage where the availability of donor&#xD;
      sites is limited.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of graft take site A vs site B</measure>
    <time_frame>&lt; 1 month</time_frame>
    <description>Clinical assessment; Image analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of graft take of all SASS</measure>
    <time_frame>&lt; 1 month</time_frame>
    <description>Clinical assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of graft take according to sites</measure>
    <time_frame>&lt; 1 month</time_frame>
    <description>Clinical assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scar evaluation site A vs site B</measure>
    <time_frame>3, 6, 12, 24 and 36 months</time_frame>
    <description>Vancouver Scar Scales; Cutometer; Mexameter; Dermascan; Images;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar evaluation according to sites</measure>
    <time_frame>3, 6, 12, 24 and 36 months</time_frame>
    <description>Cutometer; Mexameter; Dermascan; Images;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events site A vs site B</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>Clinical assessment: Infection, Hematoma below the graft, corrective surgery, inclusion of cysts, granulation buds, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of all SASS</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>Clinical assessment: Infection, Hematoma below the graft, corrective surgery, inclusion of cysts, granulation buds, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life survey</measure>
    <time_frame>3, 6, 12, 24 and 36 months</time_frame>
    <description>Survey BSHS-B ( brief version of the Burn Specific Health Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio harvested surface vs covered surface</measure>
    <time_frame>1 month</time_frame>
    <description>Planimetric analysis; Clinical assessment; Images; Image analysis;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Treatment (SASS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (split-thickness autograft)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will receive both SASS and Split-thickness autograft (paired samples).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Self assembled skin substitute (SASS)</intervention_name>
    <description>Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance.</description>
    <arm_group_label>Treatment (SASS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Split-thickness autograft</intervention_name>
    <description>Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance.</description>
    <arm_group_label>Control (split-thickness autograft)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Deep second degree burns or third degree burns over 50% TBSA (Total body surface area)&#xD;
             at time of recruitment or as determined by the surgeon;&#xD;
&#xD;
          -  Limited availability of donor sites for autografts;&#xD;
&#xD;
          -  Consent obtained by the participant or by the appropriate representative in case of&#xD;
             inapt prospective participants or minors.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Skin grafting needed only on the face, hands, feet, ears or genital area;&#xD;
&#xD;
          -  Connective tissue diseases;&#xD;
&#xD;
          -  Hypersensitivity to bovine proteins;&#xD;
&#xD;
          -  Coagulation disorders prior being burned;&#xD;
&#xD;
          -  Immunodeficiency prior being burned;&#xD;
&#xD;
          -  Uncontrolled diabetes prior being burned;&#xD;
&#xD;
          -  Permanent wound coverage before SASS grafts are ready;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François A Auger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronique J Moulin, PhD</last_name>
    <phone>418-525-4444</phone>
    <phone_ext>61715</phone_ext>
    <email>veronique.moulin@fmed.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucie Germain, PhD</last_name>
    <phone>418-525-4444</phone>
    <phone_ext>61696</phone_ext>
    <email>lucie.germain@fmed.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothill Medcial Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Gabriel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital Plastic Surgery Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Hynes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children (Sickkids)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Fish, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Bortoluzzi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Québec - Unité des grands brûlés</name>
      <address>
        <city>Québec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie Dumas, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Dr Francois A. Auger</investigator_full_name>
    <investigator_title>researcher</investigator_title>
  </responsible_party>
  <keyword>Burn wounds</keyword>
  <keyword>Burns</keyword>
  <keyword>Skin substitute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

